Acadia Pharmaceuticals (ACAD) Return on Capital Employed (2011 - 2026)

Acadia Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 6.32% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 2106.0% year-over-year to 6.32% in Q1 2026; TTM through Mar 2026 was 6.32%, a 2106.0% decrease from a year earlier, with the FY2025 full-year figure at 9.54%, down 3071.0% from the prior year.
• Return on Capital Employed eased to 6.32% in Q1 2026 per ACAD's latest filing, from 8.96% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 33.57% in Q4 2024 and bottomed at 47.62% in Q4 2022.
• The 5-year median for Return on Capital Employed is 0.97% (2024), against an average of 8.46%.
• Across the five-year window, Return on Capital Employed surged 5473 bps in 2024 and tumbled 2462 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 47.62% in 2022, then soared by 65 bps to 16.81% in 2023, then jumped by 300 bps to 33.57% in 2024, then tumbled by 73 bps to 8.96% in 2025, then dropped by 29 bps to 6.32% in 2026.
• Per Business Quant, the three latest ACAD Return on Capital Employed figures stand at 6.32% (Q1 2026), 8.96% (Q4 2025), and 26.14% (Q3 2025).